Open an account

Onkure Therapeutics

OKUR · NASDAQ

$2.36+$0.11 (+4.89%)TodayMarket closed ·
Prev close $2.25

About OKUR

OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company is headquartered in Boulder, Colorado and currently employs 45 full-time employees. The company went IPO on 2021-04-09. Using a structure-based drug design platform, the Company is building a pipeline of tumor-agnostic candidates. The company is developing OKI-219, a selective PI3KaH1047R inhibitor, as its lead program. The company is engaged in targeting oncogenic PI3Ka and has multiple programs designed to enable targeting of this key oncogene. The company is focused on delivering highly selective drug candidates that preserve wild-type PI3Ka while targeting the PI3Ka-mutated cancers, initially in advanced breast cancer. Its lead product candidate, OKI-219, is advancing in a phase I clinical trial. The company also focuses on a development candidate targeting the most common PI3Ka mutations, such as H1047R, E545K, and E542K. Additionally, it is developing an allosteric inhibitor molecule.

Employees
45
Headquarters
Boulder, Colorado
Listed
Apr 9, 2021
Sector
Health Care
Industry
Biotechnology
Website
onkuretherapeutics.com

OKUR key statistics

Market cap
95.57M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
444.28K
Volume
235.15K
Open price
$2.25
High today
$2.48
Low today
$2.25
52 Week high
$5.38
52 Week low
$2.01

Onkure Therapeutics (OKUR) at a glance

Onkure Therapeutics (OKUR) last traded at $2.36, with a market cap of 95.57M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.25 and $2.48. The current price is 4.9% above the day's low and 4.6% below its high.

Volume so far is 235.15K shares, below the average of 444.28K shares a day.

Over the past year Onkure Therapeutics has ranged from $2.01 to $5.38, and now sits 10% of the way up that range.

Onkure Therapeutics met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.31 per share against an estimate of -$0.5457.

The average analyst price target is $16.12, 582.9% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 7 analystsAvg $16.12
Low
$11.11
Now
$2.36
High
$22.05

OKUR earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 20.1% on average.

  1. Q3 FY24: reported -$1.10 per share against an estimate of -$1.05
  2. Q4 FY24: reported -$1.37 per share against an estimate of -$0.7548
  3. Q1 FY25: reported -$1.19 per share against an estimate of -$1.49
  4. Q2 FY25: reported -$1.14 per share against an estimate of -$1.27
  5. Q3 FY25: reported -$1.09 per share against an estimate of -$1.22
  6. Q4 FY25: reported -$0.99 per share against an estimate of -$1.17
  7. Q1 FY26: reported -$1.11 per share against an estimate of -$0.7574
  8. Q2 FY26: reported -$0.31 per share against an estimate of -$0.5457

OKUR news

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • Press releaseGlobe Newswire

    OnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update

  • Avi Kapoor

    This Builders FirstSource Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Similar companies

Companies in the same industry as Onkure Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.